IMACS has also developed and partially validated Preliminary Definitions of Improvement for Adult and Juvenile Myositis which combine these core set measures of disease activity and define clinically meaningful change in each of the core set activity measures. IMACS suggests that these 13 Preliminary Definitions of Improvement be used outcome measures or endpoints for all therapeutic trials in adult and juvenile myositis (see Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, Lachenbruch PA, Miller FW; International Myositis Assessment and Clinical Studies Group, International Consensus On Preliminary Definitions of Improvement for Adult and Juvenile Myositis, Arthritis Rheum., 2004 Jul, 50(7):2281-90).
|
|